Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles.

Samstein RM, Perica K, Balderrama F, Look M, Fahmy TM.

Biomaterials. 2008 Feb;29(6):703-8. Epub 2007 Nov 19.

PMID:
18006053
2.

Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment.

Westedt U, Kalinowski M, Wittmar M, Merdan T, Unger F, Fuchs J, Schäller S, Bakowsky U, Kissel T.

J Control Release. 2007 May 14;119(1):41-51. Epub 2007 Jan 26.

PMID:
17346845
3.

PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.

Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN.

J Control Release. 2007 Jun 4;119(2):197-206. Epub 2007 Feb 14.

PMID:
17399839
4.

Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.

Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN.

J Control Release. 2007 May 14;119(1):77-85. Epub 2007 Feb 3.

PMID:
17349712
5.

Nanoparticles made of fluorescence-labelled Poly(L-lactide-co-glycolide): preparation, stability, and biocompatibility.

Weiss B, Schaefer UF, Zapp J, Lamprecht A, Stallmach A, Lehr CM.

J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3048-56.

PMID:
17048517
6.

PLGA nanoparticles for the oral delivery of 5-Fluorouracil using high pressure homogenization-emulsification as the preparation method and in vitro/in vivo studies.

Li X, Xu Y, Chen G, Wei P, Ping Q.

Drug Dev Ind Pharm. 2008 Jan;34(1):107-15. doi: 10.1080/03639040701484593 .

PMID:
18214762
7.

Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats.

Sonaje K, Italia JL, Sharma G, Bhardwaj V, Tikoo K, Kumar MN.

Pharm Res. 2007 May;24(5):899-908. Epub 2007 Mar 22.

PMID:
17377747
8.

Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems.

Singh J, Pandit S, Bramwell VW, Alpar HO.

Methods. 2006 Feb;38(2):96-105.

PMID:
16442811
9.

Folic acid functionalized nanoparticles for enhanced oral drug delivery.

Roger E, Kalscheuer S, Kirtane A, Guru BR, Grill AE, Whittum-Hudson J, Panyam J.

Mol Pharm. 2012 Jul 2;9(7):2103-10. doi: 10.1021/mp2005388. Epub 2012 Jun 13.

10.

Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles.

Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K.

Int J Pharm. 2001 Jun 19;221(1-2):143-52.

PMID:
11397575
11.

Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers.

Beletsi A, Panagi Z, Avgoustakis K.

Int J Pharm. 2005 Jul 14;298(1):233-41.

PMID:
15936907
12.

Improved bioavailability of orally administered mifepristone from PLGA nanoparticles.

He W, Horn SW, Hussain MD.

Int J Pharm. 2007 Apr 4;334(1-2):173-8. Epub 2006 Oct 21.

PMID:
17101249
13.

Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution.

Yin Y, Chen D, Qiao M, Wei X, Hu H.

J Control Release. 2007 Oct 18;123(1):27-38. Epub 2007 Jul 5.

PMID:
17728000
14.

PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination.

Garinot M, Fiévez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L, Theate I, Freichels H, Jérôme C, Marchand-Brynaert J, Schneider YJ, Préat V.

J Control Release. 2007 Jul 31;120(3):195-204. Epub 2007 May 22.

PMID:
17586081
15.

The comparison of different daidzein-PLGA nanoparticles in increasing its oral bioavailability.

Ma Y, Zhao X, Li J, Shen Q.

Int J Nanomedicine. 2012;7:559-70. doi: 10.2147/IJN.S27641. Epub 2012 Feb 2.

16.

Permeation of PLGA nanoparticles across different in vitro models.

Nkabinde LA, Shoba-Zikhali LN, Semete-Makokotlela B, Kalombo L, Swai HS, Hayeshi R, Naicker B, Hillie TK, Hamman JH.

Curr Drug Deliv. 2012 Nov;9(6):617-27.

PMID:
22812395
17.

Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.

Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL.

Biomaterials. 2010 Feb;31(5):908-15. doi: 10.1016/j.biomaterials.2009.09.104. Epub 2009 Oct 22.

PMID:
19853292
18.

Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration.

Ahlin P, Kristl J, Kristl A, Vrecer F.

Int J Pharm. 2002 Jun 4;239(1-2):113-20.

PMID:
12052696
19.

PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium.

Bivas-Benita M, Romeijn S, Junginger HE, Borchard G.

Eur J Pharm Biopharm. 2004 Jul;58(1):1-6.

PMID:
15207531
20.

In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems.

Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, Swai HS.

Nanomedicine. 2010 Oct;6(5):662-71. doi: 10.1016/j.nano.2010.02.002. Epub 2010 Mar 15.

PMID:
20230912
Items per page

Supplemental Content

Write to the Help Desk